Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
13...'Bulls make money, bears make money, pigs implode ...tic toc tic toc tic
LLBO is Green...Meaning of The Color Green ... Green, the color of life, renewal, nature, and energy, is associated with meanings of growth, harmony, freshness, safety, fertility, and environment. Green is also traditionally associated with money, finances, banking, ambition, greed, jealousy, and wall street.
One way or another LLBO is all of these...13 tic toc
Squirrel, Lyn at Swiss Chamber is one sharp lady. It’s obvious she had a good conversation regarding the Launch with Cyrcadia Rob Royea who spoke to the Swiss Chamber Hong King in Oct., several weeks after some of her tweets...You are on point, good post ( many don’t like research, just want the fast food DD,let’s
keep good info. right up front).
Happy New Year to all who post here...tic toc tic toc tic
This launch may be bigger than I thought. The satellite tower they built in Ireland is huge, getting ready for the data stream.
(I discussed Cyrcadia Data Services Ireland in previous post) tic toc...
Arnie, you asked about world wide valuation all included...(least I believe it was you),
~.68 PPS given my valuation below using 10%, but with the “250,000,000 MILLION”
annual Worldwide Breast screenings (article just posted “again”) not the “80,000,0000 Million”
I previously used in my valuation. (Basically just 3.13x.22)
https://www.healthcare.siemens.nl/mammography/news/breast-cancer-screening-growing-worldwide.html
...13...tic toc tic
((Past valuation only using 80 Mil breast exams, not 250 Mil world wide exams))
Lifeline Biotechnologies
PPS Est .22 Cents
LLBO
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
Breast cancer screening: a growing world market12.07.2017
A short view on different markets
~250,000,0000 MILLION Breast Screenings Worldwide ...Say What???
“Breast cancer is the most common cancer in women worldwide, and the number of women affected continues to increase.1 There is thus a large need for early detection options.
China is therefore one of the largest markets for breast cancer screenings, along with the United States, Brazil, Japan, and Germany.” Etc etc.
https://www.healthcare.siemens.nl/mammography/news/breast-cancer-screening-growing-worldwide.html
And to think I only used a fraction of that market for valuation & there’s only one way in to the show...tic tic tic toc...
Welcome PPS ~.22—New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Previous Informative Post:
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?).
Have a good weekend my friends...
Welcome PPS ~.22—New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Previous Informative Post:
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Eva Bra :”While this method is relatively reliable, there are still crucial shortcomings, Higia Technologies’
(Eva) medical adviser Dr. Richard Kaszynski M.D., PhD told TechCrunch.”
Absolutely, that Mex device a complete copy in the sense they copied the tech., they have so far to go...I’ll probably be traveling the cosmos...iTBra is the big kid & he’s making his deveu soon.
Regardless good find that link slipped by me, but the 1st one takes you to Cyrcadia Health!!!
Also, I just contacted the writer in regards to the launch date & the fact that I believe it is the first “cancer” detection Wearable about to go to MARKET.
tic toc tic toc tic...
Rob Royea Twitter
#DailyNews, June 22, 2018 (GMT+8)
iFLYTEK, in cooperation with Cyrcadia Asia to integrate core AI technology of intelligent voice into breast cancer prevention.
#WeChat #JD #iFLYTEK #CyrcadiaAisa #Google #Facebook #Microsoft #AI #MachineLearning #DeepLearning
“WORLDS LARGEST DATABASE”
iFlytek ‘s medical department was established in 2016 and is led by Dr. Tao Xiaodong, a senior technical expert from Philips and GE Healthcare. Dr. Tao Xiaodong, General Manager of iFlytek Smart Healthcare, has extensive experience in medical imaging and computer-aided diagnostics. The iFlytek has also made rapid progress in medical + artificial intelligence in the past two years. In November 2017, the company’s “Little Doctor” artificial intelligence robot successfully passed the national medical examination, and the Chinese doctor qualification examination scored 456 points, 96 points higher than the qualified standard. In addition, iFlytek currently deploys artificial intelligence services in more than 50 hospitals in Anhui Province to provide GPs with diagnostic, therapeutic and interpretation support for medical images including breast imaging.
With the completion of this financing, iFlytek will also work with Cyrcadia Asia to explore how to integrate Cyrcadia’s technology into iFlytek ‘s medical products in China. At the same time, Dr. Tao Xiaodong also joined the board of directors of Cyrcadia Asia.
Dr. Tao Xiaodong commented on this investment: “We are very pleased to play a leading role in Cyrcadia’s technology development and market launch. iFlytek has already practiced the power of artificial intelligence in the medical field, and Cyrcadia’s technology uses metabolic changes to detect Diseases, which can overcome and compensate for the many shortcomings of current imaging technology and manual interpretation. We are also pleased with Cyrcadia’s consumer wearable device technology, which provides women with the convenience and possibility to monitor their health in real time. With the growth of the group, it is likely to become the world’s largest database of breast health and breast cancer, and we hope that in the near future we will be able to make significant contributions to the research, prevention and treatment of this disease.”
“WE ARE EXCITED. RAISED $3.6 BILLION AND “”ACCELERATING”” INVESTMENTS”
"We are excited to play a leading role in the development and launch of Cyrcadia’s technology. iFlytek is already harnessing the power of AI in healthcare, but Cyrcadia’s technology, by using metabolic change to detect disease, can leapfrog many of the current drawbacks of imaging and human interpretation. We are also excited by the promise of Cyrcadia’s technology as a consumer wearable device, providing real-time monitoring for women at their own convenience," said iFlytek Health’s CEO Tao Xiaodong.
In addition to the investment, iFlytek and Cyrcadia Asia will be exploring how to integrate Cyrcadia’s technology into iFlytek’s healthcare offering in China.
iFlytek is best known for its voice-recognition technology, but the company is also accelerating investment in other AI applications, including healthcare and smart vehicle. In May, it announced plans to raise up to RMB3.6 billion (US$567 million) through private placement to expand its artificial intelligent investments.
“SHORTCOMING IN CURRENT IMAGING TECHNOLOGIES”
Iflytek is the biggest artificial intelligence firm listed in China, and began its foray into healthcare in 2016. Dr. Tao Xiaodong, an expert with medical imaging and computer-aided diagnosis experience at Philips Healthcare and GE Healthcare, founded the department and is set to become a director at Cyrcadia Asia.
The patches detect cancer by observing metabolic changes, Tao said. This makes up for shortcoming in current imaging technologies and human interpretation, and provides a convenient way for women to monitor their health. The increasing number of users could make the service the largest breast health incidence database, and provide information for research into cancer preventions and treatments, he added.
Iflytek took quickly to the healthcare sector, and in November 2017 its AI robot Xiaoyi passed the national medical exam, the test required to qualify as a doctor in China. The bot scored 456 points, 96 more than the pass mark. The company now runs AI services at more than 50 hospitals in its home province an Anhui, helping doctors to diagnose and treat diseases and interpret medical images.
“500 MILLION PEOPLE”
Business Impact
Why 500 Million People in China Are Talking to This AI
iFlytek’s voice recognition technology is everywhere in China, and that’s what’s making it smarter every day.
by Yiting Sun September 14, 2017
In China, over 500 million people use iFlytek Input to overcome obstacles in communication such as the one Xu faces. Some also use it to send text messages through voice commands while driving, or to communicate with a speaker of another Chinese dialect. The app was developed by iFlytek, a Chinese AI company that applies deep learning in a range of fields such as speech recognition, natural-language processing, machine translation, and data mining (see “50 Smartest Companies 2017”).
“FAR AHEAD OF THE USA”
China counts on AI to find a cure for its ailing health care system
TECH NEWS
Monday, 2 Jul 2018 ?12:00 PM MYT
Read more at http://www.scmp.com/tech/china-tech/article/2153144/china-counts-ai-find-cure-its-ailing-health-ca
“China is already far ahead of the US in AI enabled diagnosis,” said Ni Hao, health care chief executive at Yitu Technology, a Shanghai-based AI start-up that specialises in facial recognition systems. There are two reasons for that, according to Ni. First, the shortage of doctors in the US is not as dire as in China, and second, US AI-start ups may not be able to afford a large medical team because American doctors earn between US$250,000.
“INITIAL
DIAGNOSIS”
iFlytek boosts use of AI in healthcare sector
2017-12-04 09:24 China Daily Editor: Wang Zihao-
Doctors there are well served by a smart, well-qualified assistant. 'She' records patients' symptoms, reviews computerized tomography scan images and makes initial diagnosis. Only, she is not human but a robot that runs on artificial intelligence.
Developed by iFlytek Co Ltd, a leading Chinese AI company, the robot aced the written test of China's national medical licensing examination-it is a test that aspiring doctors need to pass-in November, thus becoming the first device in the world to achieve the feat. It received 456 marks, 96 more than the minimum required to qualify.
In November, iFlytek was chosen by the central government as one of the four tech heavyweights to build the national AI open innovation platform by leveraging voice computing technologies.
Conclusion:
Elementary my dear Watson, the iT Bra has brilliantly timed it’s arrival in Asia, we must act fast and buy shares
of LLBO before this monster iFlytek gobbles them up. Brilliant Holmes, I was wondering just how much longer
you were going to smell this one out.
Well fellow investors we all like to talk about are investments made with are hard earned money, but this is one
I have finally reached a confidence level of enormous gratitude and realistically see a high probability of being
aquiered $$$. iFlytec Co. Is all over this, and ripe with Billions in investment money...tic toc tic
Many many years,, Cytosorbents still has no fda approval, but foreign sales & was trading
share adjusted ~.05 9 mil sales, LLBO will blow that out of the park...tic toc
LLBO door the only way in to the hottest game in town...pay up...tic toc
Welcome PPS ~.22—New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
Previous Informative Post:
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Arnie, to the moon Alice—You’re question would require some more data interpretation. But with the data transmission and receiving tower in place for the iTBra uploads to Cyrcadia Data Services Ltd., I have a warm feeling about this products potential. You cannot question the need for this product, as my previous post have
factually reported.
(Pure speculation a “USA” & Asia Launch simultaneously would undeniably send the stock up 7,600% .22, I’m busy right now valuing another Co., I’ll get back to LLBO later). Jan 13
DO NOT SELL...tic toc tic
LLBO owns 47% Cyrcadia Health
LLBO PPS Est .22
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil (2.5%)CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
In addition Cyrcadia Health & Cyrcadia Asia jointly own Cyrcadia Data Services Ltd (iTBra data input) Cyrcadia Asia also has equity shares of Cyrcadia Health adding further value to the 2.5% listed above.
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
Details in previous post...
Arnie, good point-as mentioned before this is personal, but at the same time a speculative investment.
But, this is what new & current investors should be enthusiastic about...as u know I try to stay factual in my
post, so let’s look at an enthusiastic fact (facts).
“When it comes to wearables, the AI implications are endless. This year, 75 percent of U.S consumers said technology is important for managing their health, according to a survey by Accenture. About 33 percent are incorporating wearables into their lives, up from 26 percent in 2016 (and between 2014 and 2016, use of health wearables more than doubled).”
https://www.entrepreneur.com/article/316427
Now, I don’t know about you, but that statement is very much in line with the iTBra.
Again at a holiday party last night when appropriate, I briefly discussed iTBra with several friends
wife’s (45-65 age) not one of them said NO...but YES I would try it.
( the two keys that were of interest were, 2 Hr wear time at Home & the speed of analysis vs having to waite.
I asked ok, but wouldn’t u be nervous if the results indicating a possible tumor came back & u couldn’t see your doc right away, most just said no more nervous than a hand examination & possibly findiing a lump...
So let’s all hope that someday a woman looking in the mirror sees her reflection wearing the iTBra...tic toc tic
Well shutting down the books for the year...have a great holiday to all...Jan ??? tic toc tic
LLBO owns 47% Cyrcadia Health (skip to par 4)
Calculation LLBO PPS Est .22
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil (2.5%)CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
In addition Cyrcadia Health & Cyrcadia Asia jointly own Cyrcadia Data Services Ltd (iTBra data input) Cyrcadia Asia also has equity shares of Cyrcadia Health adding further value to the 2.5% listed above.
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
Details in previous post...
Crack that wip...hey good day....05-.10-.20- ~~~~~~€Launch>
Let’s see how high this rocket can fly !
Actually that is great, good buyorders coming in... trade this puppy ...
New Investors: announcement video—the 2-part video what it is,when to market, other product avenues
(Can also be found under Media—Cyrcadiaasia.com)
https://cyrcadia.asia/2018/10/31/hkibc-all-about-money-features-rob-royea-cyrcadia-asia/#more-676
Welcome PPS ~.22—New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
Wang: Princeton University Phd researching cancer has to say about the iTBra-
““Skin patches are noninvasive, discrete, and potentially inexpensive enough that I could actually see use by common people on an ordinary basis. Specifically for Cyrcadia and iTBra™, the potential market is huge. There are over 700 million women worldwide between the ages of 20 and 70. In the United States alone, 38 million mammograms are preformed each year. Furthermore, the unacceptably high false positive rate of mammograms leads to an associated cost of over 4 billion dollars in unnecessary treatments annually in the US. If marketed correctly, iTBra™ is not only just a mammogram alternative, it could dominate the entire market
The Bottom Line
Cyrcadia sits on a very mature and proven technology that presents a solution to a “huge” market in which there is no current gold standard. This situation is unique in the startup field and I am very optimistic regarding the future success of iTBra™ and Cyrcadia.””
Tic toc tic...ground control to major Tom ...
PPS .22 ??? Or should I recalculate...let’s say on the upside
Full article link:
https://medium.com/startupreview/the-future-of-cancer-diagnostics-vol-3-e3188fefee41
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
——Details in previous post...#27131
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
——Details in previous post...#27131
Welcome —New investors: A women with the odds of 1:8 getting breast cancer over the course of her life has her hand on her breast & looks into a mirror, seeing her reflection there is no hand, but instead she is wearing the iTBra tested
& proven technology with FDA approval & she ask herself my hand for early tumor detection or proven advanced technology for $150 total annual cost which includes 12 screening uploads to Cyrcadia AI cloud data center which transmits analysis back to her & Physician (Ins Cos also if requested), in just minutes ?
So I ask you, how many lottery tickets would u buy with 1:8 odds that’s right MANY, well with over 700 Million
women between 20-60 age don’t u think we may sell some iTBras...!
Expected Asia launch Jan 2019, then world roll out. Backed by worlds largest artificial intelligence
Co-iFlytech Corp., Cisco Corp., & currently in talks with major Health Ins Co’s.
(((If u really need to know more scan this forum many good people have posted “Factual” info.,
and/or read the following POST after drinking a pot of coffee!)))
#27171 PHd cancer researcher perspective Hint: U may be induced to buy more shares!
27131 PPS it’s long,but conclusion: pps.22 or more
27094 Co marketing intent: the short “it’s happening”!
27061 Market size & Need: Summary-It’s Huge & Needed
26944 Insurance Co perspective: Ho Ho Ho Merry Christmas, AARP nailed it! $$$
27037 Number of breast cancer cases & importance of earl detection: Your life may depend on it
26370 iFlytech Corp.-Invest in healthcare through acquisition: Say what ?
25922 (now drink more coffee, lots of it), The technology, Virtual medicine growth, Mkt size, Asia/World
waiting. Other info.
Hell just buy some shares sit back & think of green grass & high tides!!!
Jim Holmes, Lifeline’sCyrcadia Health CEO commented “After over 20 years of product development, testing and validation, over $20 million of investment, 2018 is scheduled and expected to be the first year of sales of our potentially lifesaving product. Our tested and proven technology, from our multiple rounds of clinical trials, has shown early identification of breast tissue abnormalities, many of which could lead to cancers, potentially can save lives and costs. We/Cyrcadia prepared an analysis of cost savings for a presentation to a World-Wide Major Insurance Company. The medical cost comparison was identifying breast tissue abnormalities and breast cancers at stage 1-3, vs the abnormality progressing to stage 4 or 5 cancer. The cost savings was estimated at over $300,000 per patient. Applying this projected and estimated cost savings to this large insurance, was in the hundreds of millions of dollars annually. (PPS anybody’s guess ?)
.003–.0032. Nice very nice, come on in ...tic toc tic
We may see a lg block trade today (wealthy friend of mine is considering getting in we’ll see). 20-40mill shares
Nice find Squirrel...
I presented the product to the health services officer At my wife’s Companies new HQ & Xmas party yesterday.
Did not plan on doing this, but it came up in our general table conversation, next thing I know I have an audience at our table, the women were interested & info on the co & stock was given out. This Co has over 7000 women employees... Who knows maybe some more LLBO investors coming to OUR party & that’s right only one way in...
:) Skills and Expertise:
Machine Learning, Pattern Recognition, Biomedical Signal Processing, Medical Image Analysis and Biomedical Images Processing, Image Registration etc
Clinical Researcher
Software Engineer
(This is our Director of Cyrcadia Data Services Ltd domiciled in Ireland, one smart lady MSc/PhD
How busy do you think she is right now???)
*. https://www.linkedin.com/in/vinitha-sree-s-4a636956
Vinitha Sree S
Director, Analytics Core Lab, Cyrcadia HealthHouston, Texas364
Vinitha Sree Subbhuraam | MSc, PhD - ResearchGate
ResearchGate › profile ›
Oops almost forgot again ...tic toc tic
Up 16.7 Open
.15 ,I ask would you pay that PPS for a stock that has foreign trailing 12 month sales of ~$19Milliion, no FDA approval expected until 2021, no USA sales? Well many investors have & the Co is Cytosorbents ctso the
.15 pps is what ctso hit this year ($4,500,000 Million Market Cap) ON COMPARATIVE TERMS share adjusted to (((LLBO)))...LLBO.
LLBO has FDA approval, Market just waiting for the product, Launch coming, Corp backing, Cyrcadia Data Services ready to receive iTBra data, Insurance & Virtual med mkt opening their arms...tic toc
LLBO PERFORMANCE
5 Day
42.86%
1 Month
44.23%
3 Month
30.43%
YTD
57.89%
...............Ground control to major Tom...
Kingalex great find, I’ve done hrs of research on this co, tech, etc etc & I had not actually seen the Cannes presentation, thank you... oh almost forgot tic toc tic...
It’s a big tower, Earth google it Main Street N81, Blessington Ireland
Here here...so true, and I think the blood hounds are finally waking up...
U want in, Pay up the only way in to the big show...
Exactly! It's a “game changer” as Cyrcadia predicts it to be
100s other bios already and successfully using AI, & Cyrcadia
will join their ranks. Having now built Cyrcadia Data Services
& communication tower in place, ready to start receiving data
for the single largest breast cancer data bank in the world.
This Co beat out Cyrcadia Asia for most innovative Health product Asia 2018, we were one of 64, and pared against Posture360 who made it to top 12...Posture already has sales & contracts with Asia Costco retail stores.
I’d say we did pretty good, eyes are on us people & if you want in the only door is ...“”LLBO”” stock, we will be the thermometer for Cyrcadia Inc valuation & it’s going to be Global Warming...tic toc tic
William Choi-CEO Posture360
““If insurance companies want to stay relevant in this customer-first world we are in today, they must cross over the red tape, create a strong business model in collaboration with start-up companies, and take the initiative to advocate the idea internally. Additionally, time is of the essence. Insurers must act as soon as possible, because in this fast-changing world, what is relevant today may not be relevant tomorrow.”
Remember my post many months ago AARP—the Digital Doctor is in, Health trends Kaiser Permanent (who are we talking to right now that’s right Kaiser, & the unnamed Asia Ins co Rob Royea has mentioned...)
https://www.posture360.com/products/max-standard/
.0026 bid .0027 ask. Stalemate